tvtx-20240331

000143853312/31false2024Q1.02577390.03137448748748748748748720700014385332024-01-012024-03-3100014385332024-05-02xbrli:shares00014385332024-03-31iso4217:USD00014385332023-12-31iso4217:USDxbrli:shares0001438533us-gaap:ProductMember2024-01-012024-03-310001438533us-gaap:ProductMember2023-01-012023-03-310001438533us-gaap:LicenseMember2024-01-012024-03-310001438533us-gaap:LicenseMember2023-01-012023-03-3100014385332023-01-012023-03-310001438533us-gaap:CommonStockMember2023-12-310001438533us-gaap:AdditionalPaidInCapitalMember2023-12-310001438533us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001438533us-gaap:RetainedEarningsMember2023-12-310001438533us-gaap:CommonStockMember2022-12-310001438533us-gaap:AdditionalPaidInCapitalMember2022-12-310001438533us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001438533us-gaap:RetainedEarningsMember2022-12-3100014385332022-12-310001438533us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001438533us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001438533us-gaap:CommonStockMember2024-01-012024-03-310001438533us-gaap:CommonStockMember2023-01-012023-03-310001438533tvtx:UnderwrittenEquityOfferingMember2024-01-012024-03-310001438533us-gaap:CommonStockMembertvtx:UnderwrittenEquityOfferingMember2023-01-012023-03-310001438533us-gaap:AdditionalPaidInCapitalMembertvtx:UnderwrittenEquityOfferingMember2023-01-012023-03-310001438533tvtx:UnderwrittenEquityOfferingMember2023-01-012023-03-310001438533us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001438533us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001438533us-gaap:RetainedEarningsMember2024-01-012024-03-310001438533us-gaap:RetainedEarningsMember2023-01-012023-03-310001438533us-gaap:CommonStockMember2024-03-310001438533us-gaap:AdditionalPaidInCapitalMember2024-03-310001438533us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001438533us-gaap:RetainedEarningsMember2024-03-310001438533us-gaap:CommonStockMember2023-03-310001438533us-gaap:AdditionalPaidInCapitalMember2023-03-310001438533us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001438533us-gaap:RetainedEarningsMember2023-03-3100014385332023-03-310001438533tvtx:BileAcidProductPortfolioMemberus-gaap:DiscontinuedOperationsDisposedOfBySaleMember2023-08-312023-08-310001438533tvtx:BileAcidProductPortfolioMemberus-gaap:DiscontinuedOperationsDisposedOfBySaleMember2023-08-310001438533srt:MinimumMembertvtx:BileAcidProductPortfolioMemberus-gaap:DiscontinuedOperationsDisposedOfBySaleMember2023-08-312023-08-310001438533tvtx:BileAcidProductPortfolioMemberus-gaap:DiscontinuedOperationsDisposedOfBySaleMembersrt:MaximumMember2023-08-312023-08-310001438533tvtx:RegulatoryMilestoneMemberus-gaap:CollaborativeArrangementMembertvtx:ViforLtdMemberus-gaap:SubsequentEventMember2024-04-300001438533srt:ScenarioForecastMembertvtx:LigandPharmaceuticalsMemberus-gaap:CollaborativeArrangementMemberus-gaap:SubsequentEventMember2024-04-012024-06-300001438533tvtx:FILSPARIMember2024-03-31tvtx:clinicalTrial0001438533us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2024-01-310001438533srt:MinimumMember2023-12-310001438533srt:MaximumMember2023-12-3100014385332023-12-012024-03-310001438533country:USus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-03-31xbrli:puretvtx:pharmacy0001438533tvtx:TioproninProductsMember2024-01-012024-03-310001438533tvtx:TioproninProductsMember2023-01-012023-03-310001438533tvtx:FILSPARIMember2024-01-012024-03-310001438533tvtx:FILSPARIMember2023-01-012023-03-310001438533us-gaap:CollaborativeArrangementMembertvtx:ViforLtdMember2021-09-152021-09-150001438533tvtx:RegulatoryAndMarketAccessMilestoneMemberus-gaap:CollaborativeArrangementMembertvtx:ViforLtdMember2021-09-150001438533tvtx:SalesBasedMilestonePaymentsMemberus-gaap:CollaborativeArrangementMembertvtx:ViforLtdMember2021-09-150001438533us-gaap:CollaborativeArrangementMembertvtx:ViforLtdMember2021-09-15tvtx:performance_obligation0001438533tvtx:LicenseAndCollaborationMemberus-gaap:CollaborativeArrangementMembertvtx:ViforLtdMember2021-01-012021-12-310001438533tvtx:LicenseAndCollaborationMembertvtx:ViforLtdMember2024-01-012024-03-310001438533tvtx:LicenseAndCollaborationMembertvtx:ViforLtdMember2023-01-012023-03-310001438533us-gaap:CollaborativeArrangementMembertvtx:ViforLtdMember2024-03-310001438533us-gaap:CollaborativeArrangementMembertvtx:ViforLtdMember2023-12-310001438533tvtx:RenalysPharmaIncMemberus-gaap:CollaborativeArrangementMembertvtx:RegulatoryDevelopmentAndSalesBasedMilestoneMember

SEC Form 10-Q filed by Travere Therapeutics Inc.